ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks.

But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. There are plenty of strategies for discovering value stocks, but we have ...

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $29.06, along ...

A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggested big pharma may finally be willing to place ...

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company specializing in central nervous system (CNS) disorders, is navigating a critical phase of growth and expansion. With a robust ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards ...

Review the current ACADIA Pharmaceuticals Inc (ACAD:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if ACAD is the best investment for you.

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.